Heart safety check for new drug balinatunfib

NCT ID NCT07272629

Completed Knowledge-focused Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 1 study tested whether a single dose of balinatunfib affects the heart's electrical activity in 48 healthy adults aged 18 to 55. Participants received balinatunfib, a placebo, and an active control (moxifloxacin) in a crossover design. The main goal was to measure changes in the QT interval, a key heart rhythm safety marker.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: balinatunfib (also known as SAR441566)
What this could lead to: If successful, this study could show that balinatunfib is safe for the heart, supporting further development as a treatment.
What could go wrong: This is an early Phase 1 safety study in healthy volunteers, not patients. It only looks at heart rhythm effects and does not test if the drug works for any disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIAC REPOLARIZATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIAC REPOLARIZATION HEALTHY VOLUNTEERS

Contacts and locations

Locations

Fortrea Clinical Research Unit- Site Number : 8400002

Dallas, Texas, 75247, United States
Labcorp Clinical Research- Site Number : 8400001

Madison, Wisconsin, 53704, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.